Evidence map›Paper›PMID 29619569›Full record

ReviewCurrent pain and headache reports2018

America's Opioid Epidemic: a Comprehensive Review and Look into the Rising Crisis.

Peter S Ostling, Kelly S Davidson, Best O Anyama, Erik M Helander, Melville Q Wyche, Alan D Kaye

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04680741 (Application Based Addiction Treatment Adherence Trial), which is not on this map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04680741 nacompletednot on this mapstarted 2021, after this paper: background citation

Application Based Addiction Treatment Adherence Trial: a Pilot Study

TypeinterventionalSponsorThe Cleveland ClinicRan2021 to 2023Enrolled21ConditionsOpiate Use DisorderArmsAddiction Pilot App behavior tracking
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Point-of-care naloxone distribution in the emergency department: A pilot study.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Peter S OstlingDepartment of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA.
Kelly S DavidsonDepartment of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA.
Best O AnyamaDepartment of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA.
Erik M HelanderDepartment of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA.
Melville Q WycheDepartment of Pharmacology, LSUHSC, New Orleans, LA, USA.
Alan D KayeDepartment of Anesthesiology, LSUHSC, 1542 Tulane Avenue, Suite 659, New Orleans, LA, 70112, USA. akaye@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewIn the USA, there has been a sharp increase in heroin, prescription opiate, and illicitly manufactured fentanyl abuse with overdoses tripling since the 1990s. Several states have been deemed as "high-burden" abuse states where there is a greater proportion of synthetic opiate use. During the same period that prescription limitations were initially implemented throughout the country, the fentanyl epidemic started nationwide. RECENT

findingsIn the setting of data demonstrating an almost fourfold increase in overdose deaths from 1999 to 2008, states began restricting access to Food and Drug Agency (FDA) approved opioid medications. Another factor further exacerbating the opioid crises is that the cost of all formulations of naloxone has increased significantly over the past several years. In order to combat the opioid epidemic, stricter prescribing practices and prescription-monitoring programs have been instituted. Also, improvements in abuse-deterrent strategies for all opioid preparations can play an important role by increasing the safety of these medications and is a major focus of the FDA.

Indexed as

EpidemicsHumansOpioid-Related DisordersUnited StatesFentanylHeroinOpioid abuseOpioid addictionOpioid epidemicOpioid overdose

Identifiers

PMID29619569
OpenAlexW2795474226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.